FDA Clearance Tracker · P150031-S068
Vercise Genus DBS System, Vercise Gevia DBS System, Vercise PC DBS System
Last checked: Nov 20, 2026Latest source record: May 14, 2024 (this decision)Source: openFDAMethods & limitations
Decided
May 14, 2024
Approved
Time to decision
161 days
Received Dec 5, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P150031-S068
- Device name
- Vercise Genus DBS System, Vercise Gevia DBS System, Vercise PC DBS System
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Dec 5, 2023
- Decided
- May 14, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P150031
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
This updated software version only includes the enabling of the DBS Illumina 3D programming feature. All other VNN5 software functions and controls in place for programming the stimulation parameters into the implanted device and for delivering the stimulation via the implanted electrodes remain the same as the previously approved software version. The DBS Illumina 3D programming feature does not replace the need for clinical judgment in determining and finalizing the stimulation parameters that will be clinically effective for the patient, which remains the same as the previously approved software version. The device labeling has been updated with the following changes:- The VNN5 Programming Manual was updated to include the new VNN5 software version number and include instructions specific to the use of the DBS Illumina 3D programming feature.- The Clinician Programmer (CP) Software Installation Guide was updated to remove any specific mention of VNN5, thereby making the instructions more general to installing any software that will be used with the Clinician Programmer.- The DBS Reference Guide was updated to include the new VNN5 software version number and updating the document reference for the new CP Software Installation Guide.- A new Virtual Label was created for VNN5.0.1 to reflect the new software version number.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.